191 related articles for article (PubMed ID: 3364954)
21. Herpes simplex virus infection, Acyclovir and IVIG treatment all independently cause gut dysbiosis.
Ramakrishna C; Mendonca S; Ruegger PM; Kim JH; Borneman J; Cantin EM
PLoS One; 2020; 15(8):e0237189. PubMed ID: 32760124
[TBL] [Abstract][Full Text] [Related]
22. Acyclovir topical therapy of cutaneous herpes simplex virus infection in guinea pigs.
Park NH; Pavan-Langston D; McLean SL; Lass JH
Arch Dermatol; 1980 Jun; 116(6):672-5. PubMed ID: 7377804
[TBL] [Abstract][Full Text] [Related]
23. Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease.
Kristofferson A; Ericson AC; Sohl-Akerlund A; Datema R
J Gen Virol; 1988 Jun; 69 ( Pt 6)():1157-66. PubMed ID: 2838569
[TBL] [Abstract][Full Text] [Related]
24. Antiherpes effects and pharmacokinetic properties of 9-(4-hydroxybutyl) guanine and the (R) and (S) enantiomers of 9-(3,4-dihydroxybutyl)guanine.
Ericson AC; Larsson A; Aoki FY; Yisak WA; Johansson NG; Oberg B; Datema R
Antimicrob Agents Chemother; 1985 May; 27(5):753-9. PubMed ID: 2990325
[TBL] [Abstract][Full Text] [Related]
25. Novel animal model for evaluating topical efficacy of antiviral agents: flux versus efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice.
Lee PH; Su MH; Kern ER; Higuchi WI
Pharm Res; 1992 Aug; 9(8):979-89. PubMed ID: 1329068
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of topical acyclovir monophosphate, acyclovir, or penciclovir in orofacial HSV-1 infections of mice and genital HSV-2 infections of guinea pigs.
Kern ER; Palmer J; Szczech G; Painter G; Hostetler KY
Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):501-13. PubMed ID: 10772730
[TBL] [Abstract][Full Text] [Related]
27. Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice.
Lobe DC; Spector T; Ellis MN
Antiviral Res; 1991 Feb; 15(2):87-100. PubMed ID: 1650166
[TBL] [Abstract][Full Text] [Related]
28. Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir.
Larsson A; Stenberg K; Ericson AC; Haglund U; Yisak WA; Johansson NG; Oberg B; Datema R
Antimicrob Agents Chemother; 1986 Oct; 30(4):598-605. PubMed ID: 3024562
[TBL] [Abstract][Full Text] [Related]
29. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on the acute local phase of herpes simplex virus-induced skin infections in mice and the establishment of latency.
Klein RJ; Friedman-Kien AE
Antimicrob Agents Chemother; 1985 May; 27(5):763-8. PubMed ID: 3874596
[TBL] [Abstract][Full Text] [Related]
30. Effect of a thymidine kinase inhibitor (L-653,180) on antiviral treatment of experimental herpes simplex virus infection in mice.
Klein RJ; Czelusniak SM
Antiviral Res; 1990; 14(4-5):207-14. PubMed ID: 2088206
[TBL] [Abstract][Full Text] [Related]
31. Phenoxazine derivatives suppress the infections caused by herpes simplex virus type-1 and herpes simplex virus type-2 intravaginally inoculated into mice.
Hayashi K; Hayashi T; Miyazawa K; Tomoda A
J Pharmacol Sci; 2010; 114(1):85-91. PubMed ID: 20736512
[TBL] [Abstract][Full Text] [Related]
32. Effects of 2,2'-O-cyclocytidine and acyclovir on latent herpes simplex virus in trigeminal ganglia of mice.
Liu WG; Chen ZJ; Song JZ; Ma ZX
Antimicrob Agents Chemother; 1986 Feb; 29(2):278-80. PubMed ID: 2424367
[TBL] [Abstract][Full Text] [Related]
33. Influence of the treatment protocol upon the in vivo efficacy of cidofovir (HPMPC) and of acyclovir (ACV) formulations in topical treatment of cutaneous HSV-1 infection in hairless mice.
Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; DeClercq E; El-Shattawy HH
J Pharm Sci; 1999 May; 88(5):530-4. PubMed ID: 10229644
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo activity of 1-O-hexadecylpropanediol-3-phospho-ganciclovir and 1-O-hexadecylpropanediol-3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections.
Hostetler KY; Rybak RJ; Beadle JR; Gardner MF; Aldern KA; Wright KN; Kern ER
Antivir Chem Chemother; 2001 Jan; 12(1):61-70. PubMed ID: 11437323
[TBL] [Abstract][Full Text] [Related]
35. Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.
Spector T; Lobe DC; Ellis MN; Blumenkopf TA; Szczech GM
Antimicrob Agents Chemother; 1992 May; 36(5):934-7. PubMed ID: 1324641
[TBL] [Abstract][Full Text] [Related]
36. Comparison of topically applied 5-ethyl-2'-deoxyuridine and acyclovir in the treatment of cutaneous herpes simplex virus infection in guinea pigs.
Spruance SL; Freeman DJ; Sheth NV
Antimicrob Agents Chemother; 1985 Jul; 28(1):103-6. PubMed ID: 4037770
[TBL] [Abstract][Full Text] [Related]
37. Treatment of HSV-1 infection with immunoglobulin or acyclovir: comparison of their effects on viral spread, latency, and reactivation.
LeBlanc RA; Pesnicak L; Godleski M; Straus SE
Virology; 1999 Sep; 262(1):230-6. PubMed ID: 10489356
[TBL] [Abstract][Full Text] [Related]
38. Ginkgolic Acid Inhibits Herpes Simplex Virus Type 1 Skin Infection and Prevents Zosteriform Spread in Mice.
Bhutta MS; Shechter O; Gallo ES; Martin SD; Jones E; Doncel GF; Borenstein R
Viruses; 2021 Jan; 13(1):. PubMed ID: 33435520
[TBL] [Abstract][Full Text] [Related]
39. Challenges of aciclovir-resistant HSV infection in allogeneic bone marrow transplant recipients.
Anton-Vazquez V; Mehra V; Mbisa JL; Bradshaw D; Basu TN; Daly ML; Mufti GJ; Pagliuca A; Potter V; Zuckerman M
J Clin Virol; 2020 Jul; 128():104421. PubMed ID: 32417677
[TBL] [Abstract][Full Text] [Related]
40. Effect of Acyclovir Solid Lipid Nanoparticles for the Treatment of Herpes Simplex Virus (HSV) Infection in an Animal Model of HSV-1 Infection.
Kondel R; Shafiq N; Kaur IP; Singh MP; Pandey AK; Ratho RK; Malhotra S
Pharm Nanotechnol; 2019; 7(5):389-403. PubMed ID: 31465287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
